前列腺立体定向消融放疗剂量递增:两项前瞻性临床试验的远期结局
本研究比较两项前瞻性试验中长期结局:低危前列腺癌患者接受35 Gy/5次,低/中危患者接受40 Gy/5次。中位随访9.6年和6.9年,两组生化失败率无差异,4年PSA<0.4可预测生化控制,半数生化失败患者成功挽救。
要点
- 剂量递增至40 Gy/5次与35 Gy/5次相比未改善生化失败、总生存或转移-free生存。
- 4年时PSA<0.4 ng/ml者10年生化失败概率为0%,PSA≥0.4者为20.5%(p=0.02)。
- 生化失败患者中半数可通过局部挽救治疗成功管理。
核心结论
- 前列腺SABR剂量递增与更低的中位nPSA相关,但未降低生化失败率、总生存、癌症特异性生存或转移-free生存。
- 4年时PSA<0.4 ng/ml是生化控制的预测因素。
- 生化失败患者中半数可通过局部挽救成功管理。
研究设计与样本
- 比较两项前瞻性临床试验的长期结局。
- Study1纳入低危前列腺癌患者,接受35 Gy/5次(n=84)。
- Study2纳入低/中危前列腺癌患者,接受40 Gy/5次(n=30)。
- 共纳入114例患者,中位随访分别为9.6年和6.9年。
主要发现
- Study1中位nPSA为0.4 ng/ml,Study2为0.1 ng/ml。
- 9例患者出现生化失败(Study1中8例,Study2中1例)。
- Study1的5年和10年生化失败率分别为2.5%和12.8%,Study2的5年生化失败率为3.3%。
- 4年时PSA<0.4 ng/ml者生化失败概率为0%,PSA≥0.4 ng/ml者10年生化失败概率为20.5%(p=0.02)。
- 10年总生存为90.4%(p=0.25),癌症特异性生存为100%,无患者出现转移或去势抵抗。
关键数值与推荐
- 生化失败定义为PSA最低值+2 ng/ml。
- Study1剂量为35 Gy/5次,Study2剂量为40 Gy/5次。
- 4年时PSA<0.4 ng/ml者10年生化失败概率为0%,PSA≥0.4 ng/ml者为20.5%(p=0.02)。
临床怎么用
- 对于有利风险前列腺癌,35 Gy/5次与40 Gy/5次的SABR均可考虑,剂量递增未显示生化失败率获益。
- 治疗后4年PSA<0.4 ng/ml提示生化控制良好,PSA≥0.4 ng/ml需密切监测。
- 生化失败患者可考虑局部挽救治疗。
局限性
- 本研究为有利风险队列,需要更长随访以明确更低nPSA是否转化为更低的生化失败率。
- 两项试验为非随机比较,样本量有限(共114例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Optimal prostate SABR dose-fractionation is unknown. This study compares long-term outcomes from two prospective trials. METHODS: Study1 patients had low-risk PCa and received 35 Gy/5. Study2 patients had low/intermediate-risk PCa and received 40 Gy/5. Biochemical failure (BF) was defined as nadir + 2. RESULTS: 114 patients were included (study1, n = 84; study2, n = 30). Median follow-up was 9.6 years and 6.9 years. Median nPSA was 0.4 and 0.1 ng/ml. Nine patients had BF (8 in study1, 1 in study2); two were managed with ADT and four had local salvage. The BF rate was 2.5% and 12.8% at 5 and 10 years for study1 and 3.3% at 5 years for study 2. BF probability was 0% if PSA <0.4 at 4 years, and 20.5% at 10 years if PSA ≥0.4 (p = 0.02). Nine patients died, none of PCa. No patient has metastases or castrate-resistance. At 10 years, OS and CSS were 90.4% (p = 0.25) and 100%. CONCLUSIONS: Dose-escalated prostate SABR was associated with lower nPSAs but no difference in BF, OS, CSS or MFS. PSA <0.4 at 4 years was a predictor of biochemical control. Half of patients with BF were successfully salvaged. Given that this is a favorable-risk cohort, longer follow-up will be needed to see if the lower nPSA translates into lower BF rates.
引用
- Alayed Y, Cheung P, Pang G, et al. Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trials. Radiother Oncol. 2018. PMID: 29588072. doi:10.1016/j.radonc.2018.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。